Which has preferable valuation & earnings, INCY or ABBV?

AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 3.79 $1.29B $7.08 13.79 AbbVie $61.16B 6.26 $4.23B $2.03 106.70

Is INCY or ABBV more profitable?

Incyte has a net margin of 26.71% compared to AbbVie's net margin of 5.79%. Incyte's return on equity of 26.66% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 26.71% 26.66% 19.77% AbbVie 5.79% -576.45% 13.39%

Does the media refer more to INCY or ABBV?

In the previous week, AbbVie had 45 more articles in the media than Incyte. MarketBeat recorded 54 mentions for AbbVie and 9 mentions for Incyte. AbbVie's average media sentiment score of 1.14 beat Incyte's score of 0.88 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 39 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor INCY or REGN?

In the previous week, Regeneron Pharmaceuticals had 17 more articles in the media than Incyte. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 9 mentions for Incyte. Incyte's average media sentiment score of 0.88 beat Regeneron Pharmaceuticals' score of 0.72 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 14 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor ALNY or INCY?

In the previous week, Alnylam Pharmaceuticals had 4 more articles in the media than Incyte. MarketBeat recorded 13 mentions for Alnylam Pharmaceuticals and 9 mentions for Incyte. Alnylam Pharmaceuticals' average media sentiment score of 1.67 beat Incyte's score of 0.88 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Incyte 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, INCY or BIIB?

Biogen has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 3.79 $1.29B $7.08 13.79 Biogen $9.94B 2.94 $1.29B $9.32 21.22

Is INCY or BIIB more profitable?

Incyte has a net margin of 26.71% compared to Biogen's net margin of 13.81%. Incyte's return on equity of 26.66% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 26.71% 26.66% 19.77% Biogen 13.81% 12.83% 8.01%

Does the media refer more to INCY or BIIB?

In the previous week, Biogen had 6 more articles in the media than Incyte. MarketBeat recorded 15 mentions for Biogen and 9 mentions for Incyte. Incyte's average media sentiment score of 0.88 beat Biogen's score of 0.16 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor INCY or UTHR?

In the previous week, United Therapeutics had 15 more articles in the media than Incyte. MarketBeat recorded 24 mentions for United Therapeutics and 9 mentions for Incyte. Incyte's average media sentiment score of 0.88 beat United Therapeutics' score of 0.74 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 17 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Incyte (INCY) Competitors

$97.66 +0.16 (+0.16%)

As of 12:18 PM Eastern

Compare

INCY vs. ABBV, REGN, ALNY, BIIB, and UTHR

Should you buy Incyte stock or one of its competitors? MarketBeat compares Incyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Incyte include AbbVie (ABBV), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.

How does Incyte compare to AbbVie?

Incyte (NASDAQ:INCY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, AbbVie had 45 more articles in the media than Incyte. MarketBeat recorded 54 mentions for AbbVie and 9 mentions for Incyte. AbbVie's average media sentiment score of 1.14 beat Incyte's score of 0.88 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	39 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Incyte has a net margin of 26.71% compared to AbbVie's net margin of 5.79%. Incyte's return on equity of 26.66% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
AbbVie	5.79%	-576.45%	13.39%

97.0% of Incyte shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.79	$1.29B	$7.08	13.79
AbbVie	$61.16B	6.26	$4.23B	$2.03	106.70

Incyte has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Incyte currently has a consensus price target of $104.00, suggesting a potential upside of 6.50%. AbbVie has a consensus price target of $253.43, suggesting a potential upside of 17.00%. Given AbbVie's stronger consensus rating and higher possible upside, analysts clearly believe AbbVie is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Summary

AbbVie beats Incyte on 10 of the 17 factors compared between the two stocks.

How does Incyte compare to Regeneron Pharmaceuticals?

Incyte (NASDAQ:INCY) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Incyte has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 17 more articles in the media than Incyte. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 9 mentions for Incyte. Incyte's average media sentiment score of 0.88 beat Regeneron Pharmaceuticals' score of 0.72 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	14 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Incyte currently has a consensus price target of $104.00, suggesting a potential upside of 6.50%. Regeneron Pharmaceuticals has a consensus price target of $792.65, suggesting a potential upside of 28.43%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.70

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Incyte's net margin of 26.71%. Incyte's return on equity of 26.66% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

Regeneron Pharmaceuticals has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.79	$1.29B	$7.08	13.79
Regeneron Pharmaceuticals	$14.34B	4.55	$4.50B	$41.04	15.04

97.0% of Incyte shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Incyte on 11 of the 17 factors compared between the two stocks.

How does Incyte compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Incyte has a net margin of 26.71% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Incyte	26.71%	26.66%	19.77%

Alnylam Pharmaceuticals currently has a consensus price target of $463.13, suggesting a potential upside of 53.97%. Incyte has a consensus price target of $104.00, suggesting a potential upside of 6.50%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85
Incyte	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Incyte is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.29B	9.37	$313.75M	$3.66	82.18
Incyte	$5.14B	3.79	$1.29B	$7.08	13.79

Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Incyte has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

In the previous week, Alnylam Pharmaceuticals had 4 more articles in the media than Incyte. MarketBeat recorded 13 mentions for Alnylam Pharmaceuticals and 9 mentions for Incyte. Alnylam Pharmaceuticals' average media sentiment score of 1.67 beat Incyte's score of 0.88 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Incyte	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 16.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Incyte on 9 of the 17 factors compared between the two stocks.

How does Incyte compare to Biogen?

Incyte (NASDAQ:INCY) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Biogen has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.79	$1.29B	$7.08	13.79
Biogen	$9.94B	2.94	$1.29B	$9.32	21.22

Incyte has a net margin of 26.71% compared to Biogen's net margin of 13.81%. Incyte's return on equity of 26.66% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Biogen	13.81%	12.83%	8.01%

Incyte currently has a consensus target price of $104.00, indicating a potential upside of 6.50%. Biogen has a consensus target price of $215.81, indicating a potential upside of 9.11%. Given Biogen's stronger consensus rating and higher probable upside, analysts clearly believe Biogen is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Biogen	1 Sell rating(s)	13 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.52

Incyte has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Biogen has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

In the previous week, Biogen had 6 more articles in the media than Incyte. MarketBeat recorded 15 mentions for Biogen and 9 mentions for Incyte. Incyte's average media sentiment score of 0.88 beat Biogen's score of 0.16 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

97.0% of Incyte shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Biogen beats Incyte on 9 of the 17 factors compared between the two stocks.

How does Incyte compare to United Therapeutics?

Incyte (NASDAQ:INCY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

97.0% of Incyte shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Incyte has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Incyte presently has a consensus target price of $104.00, suggesting a potential upside of 6.50%. United Therapeutics has a consensus target price of $619.42, suggesting a potential upside of 12.04%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has a net margin of 40.62% compared to Incyte's net margin of 26.71%. Incyte's return on equity of 26.66% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
United Therapeutics	40.62%	19.24%	17.25%

United Therapeutics has lower revenue, but higher earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.79	$1.29B	$7.08	13.79
United Therapeutics	$3.18B	7.37	$1.33B	$27.09	20.41

In the previous week, United Therapeutics had 15 more articles in the media than Incyte. MarketBeat recorded 24 mentions for United Therapeutics and 9 mentions for Incyte. Incyte's average media sentiment score of 0.88 beat United Therapeutics' score of 0.74 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	17 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

United Therapeutics beats Incyte on 9 of the 16 factors compared between the two stocks.

Get Incyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCY vs. The Competition

Export

Metric	Incyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.51B	$3.40B	$6.42B	$12.59B
Dividend Yield	N/A	2.28%	2.75%	5.26%
P/E Ratio	13.79	18.92	21.51	26.29
Price / Sales	3.79	332.04	557.47	114.37
Price / Cash	15.75	125.26	43.49	56.90
Price / Book	3.47	7.25	10.58	7.32
Net Income	$1.29B	$24.20M	$3.56B	$337.06M
7 Day Performance	0.51%	3.83%	3.04%	3.67%
1 Month Performance	-1.46%	9.26%	6.41%	7.41%
1 Year Performance	47.87%	63.21%	36.57%	37.85%

Incyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCY Incyte	4.2497 of 5 stars	$97.66 +0.2%	$104.00 +6.5%	+50.2%	$19.51B	$5.14B	13.79	2,844
ABBV AbbVie	4.8344 of 5 stars	$209.57 -0.4%	$253.43 +20.9%	+19.5%	$371.72B	$61.16B	103.24	57,000	Trending News
REGN Regeneron Pharmaceuticals	4.9318 of 5 stars	$629.68 -9.8%	$800.57 +27.1%	+5.0%	$73.82B	$14.34B	15.34	15,410	High Trading Volume
ALNY Alnylam Pharmaceuticals	4.4609 of 5 stars	$286.27 -0.2%	$471.96 +64.9%	+6.8%	$38.32B	$3.71B	78.22	2,770	Positive News
BIIB Biogen	3.2019 of 5 stars	$191.91 -0.5%	$215.62 +12.4%	+54.0%	$28.49B	$9.89B	20.59	7,500	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCY) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incyte (INCY) Competitors

INCY vs. ABBV, REGN, ALNY, BIIB, and UTHR

How does Incyte compare to AbbVie?

Summary

How does Incyte compare to Regeneron Pharmaceuticals?

Summary

How does Incyte compare to Alnylam Pharmaceuticals?

Summary

How does Incyte compare to Biogen?

Summary

How does Incyte compare to United Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCY vs. The Competition

Incyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Incyte (INCY) Competitors

INCY vs. ABBV, REGN, ALNY, BIIB, and UTHR

How does Incyte compare to AbbVie?

Does the media refer more to INCY or ABBV?

Is INCY or ABBV more profitable?

Do insiders & institutionals have more ownership in INCY or ABBV?

Which has preferable valuation & earnings, INCY or ABBV?

Which has more risk and volatility, INCY or ABBV?

Do analysts recommend INCY or ABBV?

Summary

How does Incyte compare to Regeneron Pharmaceuticals?

Which has more volatility & risk, INCY or REGN?

Does the media favor INCY or REGN?

Do analysts recommend INCY or REGN?

Is INCY or REGN more profitable?

Which has preferable earnings & valuation, INCY or REGN?

Do institutionals & insiders hold more shares of INCY or REGN?

Summary

How does Incyte compare to Alnylam Pharmaceuticals?

Is ALNY or INCY more profitable?

Do analysts recommend ALNY or INCY?

Which has better valuation and earnings, ALNY or INCY?

Which has more volatility & risk, ALNY or INCY?

Does the media favor ALNY or INCY?

Do insiders & institutionals hold more shares of ALNY or INCY?

Summary

How does Incyte compare to Biogen?

Which has stronger earnings & valuation, INCY or BIIB?

Is INCY or BIIB more profitable?

Do analysts prefer INCY or BIIB?

Which has more risk and volatility, INCY or BIIB?

Does the media refer more to INCY or BIIB?

Do insiders and institutionals believe in INCY or BIIB?

Summary

How does Incyte compare to United Therapeutics?

Do insiders & institutionals believe in INCY or UTHR?

Which has more volatility & risk, INCY or UTHR?

Do analysts prefer INCY or UTHR?

Is INCY or UTHR more profitable?

Which has better earnings & valuation, INCY or UTHR?

Does the media favor INCY or UTHR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCY vs. The Competition

Incyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools